[Ascletis Pharmaceuticals: The US Phase II study of ASC30 in the treatment of type 2 diabetes has achieved positive top-line results] On October 29, Ascletis Pharmaceuticals announced on the Hong Kong Stock Exchange that its US Phase II study (NCT07321678) evaluating the oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in the treatment of type 2 diabetes (T2D) has achieved positive top-line results. The Phase II study is a 13-week U.S. study designed to evaluate the efficacy, safety and tolerability of once-daily oral small molecule GLP-1R agonist ASC30 tablets in 100 subjects with diabetes. The primary endpoint was the decrease in glycosylated hemoglobin (HbA1c) from baseline at week 12; one of the secondary endpoints was the decrease in body weight from baseline at week 13. ASC30 (40 mg, 60 mg, and 80 mg) met the primary endpoint and all secondary endpoints, achieving significant reductions in HbA1c and weight loss, and improving multiple cardiovascular risk factors. Type 2 diabetes is ASC30’s second indication in development beyond obesity.